Medicare Will Pick Drugs For Negotiation Based On Gross Sales, Disadvantaging Highly-Rebated Products
But on the bright side, knowing that eligibility will not be based on net sales to Medicare makes it easier to predict which drugs will be selected first.
You may also be interested in...
Medicare Price Negotiations: Competitors’ Net Prices, Clinical Benefit Are ‘Starting Point’ For Initial Offer
CMS chose the prices of therapeutic alternatives and these competitors’ comparative benefits as the ‘foundation and starting point’ for setting an initial offer for drugs subject to negotiation, ahead of other factors Congress laid out it could consider that are more singularly focused on the specific drug at issue.
Medicare Use Of Gross Rx Prices In Negotiation Picks Would Limit Savings, Erode Rebates – Payers
United Health Group and CVS strongly object to CMS’s proposed approach to selecting Part D drugs for price negotiation. United Health suggests the agency's method of announcing it will use gross, instead of net, costs could constitute a violation of the Administrative Procedure Act.
Medicare Price Negotiation: Special Treatment For ‘Novel Technologies’ On PhRMA’s Advocacy Agenda
Novartis CEO Vasant Narasimhan, PhRMA's incoming board chair, says in an interview that the brand drug association has a slate of issues to pursue as it works to shape the implementation of the Medicare price negotiation program in the name of preserving innovation.